Here's why we took a position in the iShares NASDAQ Biotechnology Index.
Four myths on the corporate tax dodging debate
These misunderstandings aren't helping anyone.
Hedge funds' abysmal performance so far in 2013
Not only did hedge funds as a class underperform the S&P 500 by fully 10% through May 10, but only a small sliver of funds managed to outperform it.
Jeffrey Gundlach: I'd short Chipotle at $380 and avoid everything Apple
"I've been all dollar, all the time."
Five takeaways from the global commodities rout
It's now reaching far and wide.
The music industry gets its groove back
Google's new music streaming service is good news for the industry.
Carter Lecraw: Aligning stock picks with American Values
Carter Lecraw discusses his red, white and blue investing philosophy.
Is the market still cheap?
The debate over stock valuations rages on.
CEOs are increasingly gloomy about the earnings outlook
Earnings guidance was negative for seventh straight quarter.
Barry Randall: Cerner is a fleet flooted giant
Cerner is a standout, says Barry Randall.